

New treatment approach - Retrospective pilot study shows that PiezoWave² with the linear Therapy Source reduced postherpetic neuralgia (PHN) associated pain and itch.

A Korean research group is currently publishing a pilot study on the shockwave treatment of postherpetic neuralgia. The most common neurological complications associated with **herpes zoster** is **postherpetic neuralgia (PHN)**, defined as pain lasting for 90 days after the onset of rash. PHN is characterized by neuropathic pain, including a persistent spontaneous sharp or paroxysmal burning sensation, allodynia, and/or hyperesthesia, that affects patient quality of life. Of patients >50 years of age, approximately 10% to 15% with herpes zoster develop PHN (this means about 50.000 in Germany), and this complication occurs more often in older patients.

This procedure is not part of the intended use of the PiezoWave² ; FBL10xG2 and must be considered as off label use. We would also expect that this procedure will interest many scientifically active ESWT physicians. Please inform your contact partners. The linear source is certainly uniquely suited for this application.

The treatment protocol of the authors can be found in the attached study.

Observational Study

Medicine[®]

OPEN

Efficacy of extracorporeal shockwave therapy in the treatment of postherpetic neuralgia

A pilot study

Sung Hyun Lee, MD^a, Kyoung-Ho Ryu, MD^{a,*}, Pyoung On Kim, MD^a, Hyo-Won Lee, MD^a, Eun-Ah Cho, MD^a, Jin-Hee Ahn, MD^a, Inyoung Youn, MD^b, Kyung Seung Yang, MD^c

// *...To our knowledge, this is the first report to describe the use of ESWT in PHN patients...We found that ESWT was clinically useful as a noninvasive therapy for pain and itch associated with PHN, and can be considered an effective alternative modality for the treatment of PHN and PHI...* //